Effect of ultrasound on herpes simplex virus infection in cell culture

Virology Journal

Volumn 8, Issue , 2011, Pages

  Shintani, Motoko ^a   Takahashi, Gen ^a   Hamada, Masakazu ^a   Okunaga, Shyusuke ^a   Iwai, Soichi ^a   Yura, Yoshiaki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC HERPES VIRUS;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN TISSUE; MICROBUBBLE; NONHUMAN; ONCOLYTIC VIROTHERAPY; SQUAMOUS CELL CARCINOMA; ULTRASOUND; VERO CELL; VIRUS ENTRY; VIRUS PLAQUE; ANIMAL; CELL SURVIVAL; CERCOPITHECUS; DRUG EFFECT; METHODOLOGY; MOUSE; MOUTH TUMOR; PATHOLOGY; PHYSIOLOGY; RADIATION EXPOSURE; SOUND; TUMOR CELL LINE; VIROLOGY; VIRUS CULTURE; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MICE; MICROBUBBLES; MOUTH NEOPLASMS; ONCOLYTIC VIROTHERAPY; SOUND; VERO CELLS; VIRAL PLAQUE ASSAY; VIRUS REPLICATION;

EID: 80053174048     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-446     Document Type: Article

References (37)

1. Experimental therapy of human glioma by means of genetically engineered virus mutant. Martuza RL, Malick A, Market JM, Ruffner KL, Coen DM, Science 1991 252 854 856 10.1126/science.1851332 1851332 (Pubitemid 121000529)
2. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, Landers S, Maples P, Romel L, Randlev B, Reid T, Kaye S, Kirn D, Cancer Res 2000 15 6359 6366
3. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ, Blood 2004 103 1641 1646 10.1182/blood-2003-07-2233 14604966 (Pubitemid 38268954)
4. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Nakamori M, Fu X, Rousseau R, Chen SY, Zhang X, Mol Ther 2004 9 658 665 10.1016/j.ymthe.2004. 02.019 15120326 (Pubitemid 38660418)
5. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL, Nat Med 1995 1 938 943 10.1038/nm0995-938 7585221
6. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L, Guilfoyle B, Haag NP, Karrasch M, Glasschroeder B, Knoll A, Getrajdman G, Kowal KJ, Jarnagin WR, Fong Y, Hum Gene Ther 2006 17 1214 1224 10.1089/hum.2006.17.1214 17107303 (Pubitemid 44975138)
7. Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Mace AT, Ganly I, Soutar DS, Brown SM, Head Neck 2008 30 1045 1051 10.1002/hed.20840 18615711
8. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Boucher Y, Baxter LT, Jain RK, Cancer Res 1990 50 4478 4484 2369726 (Pubitemid 20230379)
9. Normalization of tumor vasculature: an emerging concept inantiangiogenic therapy. Jain RK, Science 2005 307 58 62 10.1126/science.1104819 15637262 (Pubitemid 40093472)
10. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK, Cancer Res 2006 66 2509 2513 10.1158/0008-5472.CAN-05-2242 16510565
11. Delivery of viral vectors to tumor cells: extracellular transport, systemic distribution, and strategies for improvement. Wang Y, Yuan F, Ann Biomed Eng 2006 34 114 127 10.1007/s10439-005-9007-2 16520902
12. Molecular imaging with contrast ultrasound and targeted microbubbles. Lindner JR, J Nucl Cardiol 2004 11 215 221 10.1016/j.nuclcard.2004.01.003 15052252 (Pubitemid 38949915)
13. Molecular imaging with targeted contrast ultrasound. Kaufmann BA, Lindner JR, Curr Opin Biotechnol 2007 18 11 16 10.1016/j.copbio.2007.01.004 17241779 (Pubitemid 46237740)
14. The effects of continuous wave and pulsed ultrasound on rat thymocytes in vitro. Dooley DA, Child SZ, Carstensen EL, Miller MW, Ultrasound Med Biol 1983 9 379 384 10.1016/0301-5629(83)90091-1 6649156 (Pubitemid 14241970)
15. Transfection of mammalian cells with plasmid DNA by scrape loading and sonication loading. Fechheimer M, Boylan JF, Parker S, Sisken JE, Patel GL, Zimmer SG, Proc Natl Acad Sci USA 1987 84 8463 8467 10.1073/pnas.84.23.8463 2446324
16. Ultrasound gene therapy: on the road from concept to reality. Newman CM, Lawrie A, Brisken AF, Cumberland DC, Echocardiography 2001 18 339 347 10.1046/j.1540-8175.2001.00339.x 11415507 (Pubitemid 32579097)
17. Ultrasound mediated delivery of drugs and genes to solid tumors. Frenkel V, Adv Drug Deliv Rev 2008 60 1193 1208 10.1016/j.addr.2008.03.007 18474406
18. Enhanced retroviral gene delivery in ultrasonic standing wave fields. Lee YH, Peng CA, Gene Ther 2005 12 625 633 10.1038/sj.gt.3302444 15647763 (Pubitemid 40468110)
19. Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents. Howard CM, Forsberg F, Minimo C, Liu JB, Merton DA, Claudio PP, J Cell Physiol 2006 209 413 421 10.1002/jcp.20736 16883597 (Pubitemid 44484632)
20. Targeted retroviral gene delivery using ultrasound. Taylor SL, Rahim AA, Bush NL, Bamber JC, Porter CD, J Gene Med 2007 9 77 87 10.1002/jgm.1003 17310476 (Pubitemid 46444485)
21. Ultrasound-targeted microbubble destruction enhances AAV-mediated gene transfection in human RPE cells in vitro and rat retina in vivo. Li HL, Zheng XZ, Wang HP, Li F, Wu Y, Du LF, Gene Ther 2009 16 1146 1153 10.1038/gt.2009.84 19571889
22. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ, Cancer Res 1997 57 1502 1509 9108452 (Pubitemid 27175567)
23. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Takakuwa H, Goshima F, Nozawa N, Yoshikawa T, Kimata H, Nakao A, Nawa A, Kurata T, Sata T, Nishiyama Y, Arch Virol 2003 148 813 825 10.1007/s00705-002-0944-x 12664303 (Pubitemid 36425166)
24. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Ogawa F, Takaoka H, Iwai S, Aota K, Yura Y, Anticancer Res 2008 28 3637 3645 19189645
25. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide. Naito S, Obayashi S, Sumi T, Iwai S, Nakazawa M, Ikuta K, Yura Y, Cancer Gene Ther 2006 13 780 791 10.1038/sj.cgt.7700957 16645620 (Pubitemid 44100491)
26. Transfection effect of microbubbles on cells in superposed ultrasound waves and behavior of cavitation bubble. Kodama T, Tomita Y, Koshiyama K, Blomley MJ, Ultrasound Med Biol 2006 32 905 914 10.1016/j.ultrasmedbio.2006.03. 004 16785012 (Pubitemid 43903085)
27. Sonodynamic therapy. Tachibana K, Feril LB Jr, Ikeda-Dantsuji Y, Ultrasonics 2008 48 253 259 10.1016/j.ultras.2008.02.003 18433819
28. Local delivery system of cytotoxic agents to tumors by focused sonoporation. Iwanaga K, Tominaga K, Yamamoto K, Habu M, Maeda H, Akifusa S, Tsujisawa T, Okinaga T, Fukuda J, Nishihara T, Cancer Gene Ther 2007 14 354 363 10.1038/sj.cgt.7701026 17273182 (Pubitemid 46425785)
29. Low-intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin. Watanabe Y, Aoi A, Horie S, Tomita N, Mori S, Morikawa H, Matsumura Y, Vassaux G, Kodama T, Cancer Sci 2008 99 2525 2531 10.1111/j.1349-7006.2008. 00989.x 19018767
30. Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice - initial results. Li T, Tachibana K, Kuroki M, Kuroki M, Radiology 2003 229 423 428 10.1148/radiol.2292020500 14512507 (Pubitemid 37310829)
31. Calibration of the 1-MHz Sonitron ultrasound system. Kopechek JA, Kim H, McPherson DD, Holland CK, Ultrasound Med Biol 2010 36 1762 1766 10.1016/j.ultrasmedbio.2010.05.020 20800963
32. An echo-contrast agent, Levovist, lowers the ultrasound intensity required to induce apoptosis of human leukemia cells. Ando H, Feril LB Jr, Kondo T, Tabuchi Y, Ogawa R, Zhao QL, Cui ZG, Umemura S, Yoshikawa H, Misaki T, Cancer Lett 2006 242 37 45 10.1016/j.canlet.2005.10.032 16377079 (Pubitemid 44485291)
33. Enhancing ultrasound-mediated cell membrane permeabilisation (sonoporation) using a high frequency pulse regime and implications for ultrasound-aided cancer chemotherapy. Li YS, Reid CN, McHale AP, Cancer Lett 2008 266 156 162 10.1016/j.canlet.2008.02.041 18367324
34. Different receptors binding to distinct interfaces on herpes simplex virus gD can trigger events leading to cell fusion and viral entry. Spear PG, Manoj S, Yoon M, Jogger CR, Zago A, Myscofski D, Virology 2006 344 17 24 10.1016/j.virol.2005.09.016 16364731 (Pubitemid 41814445)
35. The multipartite system that mediates entry of herpes simplex virus into the cell. Campadelli-Fiume G, Amasio M, Avitabile E, Cerretani A, Forghieri C, Gianni T, Menotti L, Rev Med Virol 2007 17 313 326 10.1002/rmv.546 17573668 (Pubitemid 47425869)
36. Understanding HSV-1 entry glycoproteins. Reske A, Pollara G, Krummenacher C, Chain BM, Katz DR, Rev Med Virol 2007 17 205 215 10.1002/rmv.531 17295428 (Pubitemid 46827223)
37. Microbubbles in ultrasound-triggered drug and gene delivery. Hernot S, Klibanov AL, Adv Drug Deliv Rev 2008 60 1153 1166 10.1016/j.addr.2008.03.005 18486268